LEXICON PHARMACEUTICALS, INC. Retained Earnings
LEXICON PHARMACEUTICALS, INC. (LXRX) had Retained Earnings of -$2.05 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$2.05B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$2.02B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$2.02B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$2.00B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$2.05B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$2.02B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$2.02B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$2.00B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$1.99B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$1.99B 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$1.97B 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$1.93B 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$1.87B 10-Q · filed 2024-08-02 | |
| 2024-03-31 | -$1.82B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | -$1.77B 10-K · filed 2025-03-07 | |
| 2023-09-30 | -$1.72B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$1.67B 10-Q · filed 2023-08-04 | |
| 2023-03-31 | -$1.62B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | -$1.59B 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$1.56B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$1.54B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | -$1.51B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$1.49B 10-K · filed 2023-03-03 | |
| 2021-09-30 | -$1.46B 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$1.44B 10-Q · filed 2021-08-06 | |
| 2021-03-31 | -$1.42B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | -$1.40B 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$1.39B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | -$1.48B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | -$1.41B 10-Q · filed 2020-04-27 | |
| 2019-12-31 | -$1.34B 10-K · filed 2021-03-12 | |
| 2019-09-30 | -$1.29B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | -$1.52B 10-Q · filed 2019-08-01 | |
| 2019-03-31 | -$1.49B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | -$1.47B 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$1.47B 10-Q · filed 2018-11-01 | |
| 2018-06-30 | -$1.44B 10-Q · filed 2018-07-30 | |
| 2018-03-31 | -$1.41B 10-Q · filed 2018-05-03 | |
| 2017-12-31 | -$1.37B 10-K · filed 2019-03-15 | -$1.38B 10-K · filed 2018-03-01 |
| 2017-09-30 | -$1.35B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$1.32B 10-Q · filed 2017-08-01 | |
| 2017-03-31 | -$1.29B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$1.25B 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$1.22B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | -$1.18B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$1.14B 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$1.11B 10-K · filed 2017-03-06 | |
| 2015-09-30 | -$1.20B 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$1.16B 10-Q · filed 2015-08-07 | |
| 2015-03-31 | -$1.13B 10-Q · filed 2015-05-05 | |
| 2014-12-31 | -$1.10B 10-K · filed 2016-03-11 | |
| 2014-09-30 | -$1.10B 10-Q · filed 2014-11-06 | |
| 2014-06-30 | -$1.06B 10-Q · filed 2014-08-07 | |
| 2014-03-31 | -$1.03B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | -$1.00B 10-K · filed 2015-03-12 | |
| 2013-09-30 | -$986.54M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | -$954.89M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | -$925.81M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | -$899.83M 10-K · filed 2014-03-07 | |
| 2012-09-30 | -$874.96M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | -$845.42M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | -$819.49M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | -$789.62M 10-K · filed 2013-03-11 | |
| 2011-09-30 | -$755.78M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | -$729.67M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | -$673.41M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |